Shingles Vaccines Market Size, Share & Industry Analysis, By Type (Recombinant/Conjugate/Subunit and Others), By Product (SHINGRIX and Others), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others), and Regional Forecast, 2025-2032

The global shingles vaccines market size was valued at USD 5.62 billion in 2024. The market is expected to grow from USD 5.67 billion in 2025 to USD 10.21 billion by 2032, exhibiting a CAGR of 8.8% during the forecast period. North America dominated the shingles vaccines market with a market share of 36.29% in 2024.

Shingles vaccines are used to prevent shingles (herpes zoster), a painful rash caused by the varicella-zoster virus, and are recommended for adults. Varicella-zoster virus (VZV) is the same virus that causes chickenpox. After a person has chickenpox, the virus remains inactive in the human body and later reactivates as shingles. While anyone who has had chickenpox can get shingles, it is more common in older adults.

The rise in the prevalence of shingles, increasing awareness programs, and an aging population drives the market growth. The robust pipeline and high research and development also support the market growth during the forecast period.

• For instance, according to the data published by the Centers for Disease Control and Prevention in July 2024, vaccination is the only way to protect against shingles disease. This vaccine is given in two-doses.

Some of the key operating players in the market include Pfizer Inc. and GSK plc. The robust pipeline and product launches by these key market players also boost the market growth during the forecast period.

MARKET DYNAMICS

MARKET DRIVERS

Rising Cases of Shingles to Drive Market Growth

The rising incidence of shingles disease across the globe primarily drives the market growth. The increasing geriatric population and natural decline in the immune system are responsible for the increase in the cases of shingles, as elderly population is more susceptible to this disease. Rise in incidences increases the demand for more effective vaccines. Additionally, rising awareness regarding preventive measures among people further increases the adoption rate of these vaccines and thereby supports the shingles vaccines market growth.

• For instance, according to the data published by the National Center for Biotechnology Information in September 2023, the prevalence of shingles in younger healthy adults is 1.2 to 3.4 per 1000 persons per year at global level.

MARKET RESTRAINTS

Side Effects of Vaccines May Limit Market Expansion

The side effects of the shingles vaccine may hamper the market growth during the forecast period. Some serious side effects, such as allergic reactions or increased risk of Guillain-Barre syndrome, can lower consumer trust and reduce vaccine adoption rates. Common side effects, such as pain, redness, or swelling at the injection site and fatigue or fever, also hamper the product uptake. With high side effects, the shingles vaccine was discontinued by the government, leading to lower market growth.

• For instance, in 2023, the Canadian government discontinued Zostavax, the first approved shingles vaccine, due to its side effects, such as diarrhea, joint pain, and others.

MARKET OPPORTUNITIES

Addressing Cost Barriers Offers Lucrative Growth Opportunities

Addressing cost barriers, such as high vaccine costs and lack of insurance coverage, presents a significant opportunity for growth and increasing vaccination rates. By making vaccines more affordable and accessible, especially for vulnerable populations, the market can expand and provide better protection to individuals against shingles and its complications. Additionally, cost-effective vaccines may increase the product adoption rate, which is expected to boost market growth in the future.

• For instance, according to the data published by Sahyadri Hospital, in February 2025, the total cost of two doses of Shingrix is USD 300 - 400 (₹26,000 to ₹34,000) in India. By lowering these prices, the uptake of vaccines may increase in future leading to notable market growth.

MARKET CHALLENGES

Limited Awareness and Access May Act as a Hurdle to Market’s Growth

The limited awareness among the general population includes a lack of understanding about shingles disease, and its risks and misconceptions about the vaccine's safety and efficacy. This lack of awareness can lead to low vaccination rates, leaving individuals vulnerable to shingles and its complications. All these factors result in limiting the market’s growth during the forecast period.

• For instance, according to the experiment conducted by the National Center for Biotechnology Information, in October 2023, 57.2% of participants had heard about the shingles vaccine among 402 participants. Still, only 7.7% received the vaccine in Saudi Arabia.

Shingles Vaccines Market Trends

Increasing Adoption of Recombinant Subunit Vaccines is a Prominent Market Trend

The market is observing an increase in the adoption rate of recombinant subunit vaccines. The rise in the demand for accurate, effective, and safer vaccines is responsible for boosting this trend. The recombinant subunit vaccine, such as SHINGRIX, is gaining preference due to their high efficacy and safety profile, especially for older and immunocompromised individuals. The ZOSTAVAX, a live attenuated vaccine, is discontinued in Canada and the U.S. because it has low efficacy and safety. Additionally, the recombinant subunit vaccines are also useful in treating other complications of shingles disease, which is expected to increase usage of these products.

• For instance, according to the data published by the CDC, in July 2024, the recombinant shingles vaccine also protects postherpetic neuralgia (PHN), a common complication from shingles. It’s a long-term nerve pain in the same area as the shingles rash.

Download Free sample to learn more about this report.

Segmentation Analysis

By Type

High Efficacy and Safety Drives Growth of Recombinant/Conjugate/Subunit Segment 

Based on type, the market is segmented into recombinant/conjugate/subunit and others. 

The recombinant/conjugate/subunit segment dominated in 2024 and is anticipated to record the fastest-growth during the forecast period. The dominance of the segment is attributed to its high efficacy and safety. This segment contains non-live vaccines, which makes it safer for individuals with weakened immune systems. These vaccine types use specific antigens, such as weakened viruses, to reduce the risk of complications and provide high protection against shingles. Additionally, these vaccines not only protect against shingles but also lower the risk of other diseases, such as dementia.

The others segment includes mRNA and various vaccines. The mRNA based vaccines are being actively researched and developed as potential alternatives. These vaccines are expected to address some of the adverse reactions associated with recombinant vaccines, and potentially improve the durability of protection.

• For instance, in May 2025, AIM Vaccine announced that they received clinical trial approval for mRNA Shingles Shot from People's Republic of China’s (PRC's) Center for Drug Evaluation (CDE).

By Product

High Demand and Effectiveness of SHINGRIX Leads to its Dominance

Based on product, the market is segmented into SHINGRIX and others.

The SHINGRIX segment dominated with the highest shingles vaccines market share in 2024. SHINGRIX is a recombinant subunit adjuvant vaccine, which is given in two doses, typically 2 to 6 months apart. The segment dominates as it is highly effective, safe, and provides strong protection against shingles and its complications such as postherpetic neuralgia.

• For instance, according to the data published by the Centers for Disease Control and Prevention in July 2024, SHINGRIX is 97% proficient in preventing individuals from shingles between the age group of 50 and 69.

The others segment includes pipeline products, such as mRNA based vaccines. In today's landscape, safety is the major concern regarding shingles vaccines, resulting in a surge in the advancement of non-live vaccines.

By Distribution Channel

Government Suppliers is Leading Distribution Channel Owing to Rise in Public Health Initiatives

Based on distribution channel, the market is segmented into hospital & retail pharmacies, government suppliers, and others.

The government suppliers segment held the largest share of the market in 2024. The segment's superior position is due to the rise in public health initiatives and immunization programs by government suppliers, such as Global Alliance for Vaccines and Immunization (GAVI). The favorable reimbursement policies for shingles vaccines make them more accessible and affordable for individuals.

The hospital & retail pharmacies segment is expected to account for a considerable market share during the forecast period. Increase in public-private partnerships with advanced healthcare facilities and a rise in hospital patient flow augment the segment's growth.

• For instance, in February 2025, FV Hospital introduced Shingrix vaccines in its offerings to provide protection against shingles disease.

Shingles Vaccines Market Regional Outlook

By region, the market is fragmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America dominated the global shingles vaccines market and generated USD 2.04 billion in 2024. Key factors contributing to the regional dominance include the high usage of shingles vaccines due to high prevalence of shingles disease in the region.

U.S.

The U.S. market dominated the North American market with the largest share in 2024. The rise in the cases of shingles disease and the increase in awareness about preventive measures, such as vaccination, drives growth of the regional market. Strong government support for vaccination programs and a high vaccine adoption rate also support the country’s growth.

• For instance, according to the data published by CDC in June 2024, in the U.S., approximately 1 in 3 people developed shingles (herpes zoster) in their lifetime. The estimated annual cases of shingles disease are 1 million.

Europe

Europe is the second-dominating region in the market. The European market benefits from favorable reimbursement policies for vaccines, which increases the adoption rate of products. Additionally, a rise in awareness, particularly in rural and underserved areas, drives the region’s growth. 

• For instance, according to the data published by the European Pain Federation EFIC in February 2023, the International Federation on Ageing (IFA) hosted shingles awareness week across the European Union in collaboration with GSK to renew the commitment to increasing awareness of shingles.

Asia Pacific

Asia Pacific is the fastest-growing region of the global market. The regional growth is attributed to the rising elderly population, increasing disposable income, and high R&D investment. Additionally, government initiatives and rising awareness about the disease and its prevention supports the market growth. Key market players are also contributing to increase in the awareness among people through awareness campaigns.

• For instance, according to the data published by BioPharma APAC, in February 2023, GSK plc. hosted the Shingles Awareness Week that aims to educate Singaporeans about shingles disease and increase the importance of protection against it.

Latin America and the Middle East & Africa

The market in Latin America and the Middle East & Africa is anticipated to witness considerable growth in the near future. The rise in awareness about shingles disease and government initiatives, such as immunization coverage and the introduction of more effective vaccines, support this region's market growth.

COMPETITIVE LANDSCAPE

Key Industry Players

Companies Focus on Novel Product Launches and Shingles Awareness Campaigns to Gain Edge

The global market is concentrated with companies such as GSK plc. and Pfizer Inc. accounting for a significant share.

GSK plc. is a major player in the market and its SHINGRIX vaccine is a highly effective and widely adopted product. The company held shingles awareness campaigns in various regions, which increased product adoption rate. Additionally, GSK plc. has a strong global presence and collaborations with other global organizations, in turn driving the company's growth.

• For instance, in January 2025, GSK plc. announced that their regulatory application for prefilled syringe presentation of Shingrix for the prevention of shingles was accepted by the U.S. FDA for review.

Pfizer Inc. is anticipated to capture a significant share of the market and the company is developing mRNA based singles vaccine with BioNTech. Additionally, its strong global presence and clinical success further drive the company's growth. 

Moderna Inc., Jiangsu Recbio Technology Co., Ltd., Dynavax Technologies, and Curevo Inc. are among the other prominent players. These market players are focusing on the development of new shingles vaccines.

LIST OF KEY SHINGLES VACCINES COMPANIES PROFILED

• GSK plc. (U.K.)
• Moderna Inc. (U.S.)
• Jiangsu Recbio Technology Co., Ltd. (China)
• Pfizer Inc. (U.S.)
• Dynavax Technologies (U.S.)
• Curevo Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS

• December 2024: GSK plc. and Chongqing Zhifei Biological Products, Ltd. entered into an agreement that aims to revise terms on which Zhifei will commercialize SHINGRIX, GSK’s shingles vaccine in China.
• May 2024: Dynavax Technologies announced that Z-1018, an investigational vaccine candidate, is being developed to prevent shingles in adults aged 50 years and older.
• October 2023: Jiangsu Recbio Technology Co., Ltd. received clinical trial approval notice in China from the National Medical Products Administration (NMPA) for REC610, a novel adjuvanted recombinant shingles vaccine.
• June 2023: GSK plc. received approval for SHINGRIX for the prevention of shingles in at-risk adults aged 18 and over from the Japanese Ministry of Health, Labour and Welfare (MHLW).
• February 2023: Pfizer Inc. and BioNTech SE started a phase 1/2 trial study to check the safety, tolerability, and immunogenicity of the first mRNA-based shingles vaccine.

REPORT COVERAGE

The global shingles vaccines market report provides market size & forecast by all the segments. It includes details on the market dynamics and market trends expected to drive the market in the forecast period. It offers information on prevalence of shingles disease in key regions/countries, key industry developments, new product launches, details on partnerships, and mergers & acquisitions. It covers a detailed competitive landscape with information on the market share and profiles of key players.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation